Novartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2022

  1. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results

    Leukemia, Vol. 36, Núm. 1, pp. 90-99

2021

  1. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial

    Leukemia, Vol. 35, Núm. 9, pp. 2539-2551

2020

  1. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

    Blood, Vol. 135, Núm. 5, pp. 371-380

  2. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial

    Blood Advances, Vol. 4, Núm. 19, pp. 4945-4954